Novome Biotechnologies

Executive Summary

Novome Biotechnologies is a clinical-stage biotechnology company pioneering engineered microbial medicines for chronic diseases. Its platform genetically modifies specific gut bacterial strains to colonize the intestine and locally produce therapeutic molecules, offering a novel approach to treat conditions with high unmet need. The company’s lead programs target primary hyperoxaluria type 1 (PH1) and inflammatory bowel disease (IBD), both of which have progressed to Phase 2 clinical trials. With $43.5 million raised to date, Novome is well-positioned to advance its pipeline. The PH1 program aims to reduce urinary oxalate levels by degrading oxalate in the gut, while the IBD program focuses on delivering anti-inflammatory proteins directly to the gut mucosa. Novome’s strategy leverages the growing understanding of the gut microbiome and has the potential to improve efficacy and reduce systemic side effects compared to conventional therapies.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for hyperoxaluria program40% success
• Q4 2026Phase 2 data readout for IBD program30% success
• H1 2026Potential Series C financing round60% success